Abstract
Acute thrombotic lower limb ischemia is a limb- and life-threatening event. Catheter-directed thrombolysis is now one of the best choices in treatment of such condition. Tissue plasminogen activator like alteplase is a safe and efficient thrombolytic agent. The current study is designed to show its efficacy and safety and to investigate variables that correlate with outcome. This is a prospective observational study. It included patients with acute thrombotic lower limb ischemia. Exclusion criteria include acute lower limb ischemia due to embolism, trauma, arterial dissection, complicated aneurysm. Patients with bleeding risk, history of recent intracranial bleeding, massive gangrene, or uncontrolled hypertension are also excluded. The study is approved by ethical committee of Beni-Suef University and assigned number FWA00015574. Primary end points were technical success, clinical success, and limb salvage. Secondary end points were procedural complications. A total of 36 patients were enrolled in the study from March 2019 to February 2021 in Beni-Suef University hospital. It included 21 male patients (58.33%) and 15 female patients (41.67%). The patient’s mean age was 58.42 years. The patient’s mean BMI was 31.56.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
